Risk factors for severe and critically ill COVID‐19 patients: A review

The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID‐19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID‐19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high‐sensitivity C‐reactive protein, proinflammatory cytokines such as interleukin (IL)‐6, IL‐1β, Krebs von den Lungen‐6 (KL‐6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID‐19.

[1]  Bijal A. Parikh,et al.  Comparison of Upper Respiratory Viral Load Distributions in Asymptomatic and Symptomatic Children Diagnosed with SARS-CoV-2 Infection in Pediatric Hospital Testing Programs , 2020, Journal of Clinical Microbiology.

[2]  P. Schmid‐Grendelmeier,et al.  Benralizumab for severe DRESS in two COVID-19 patients , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[3]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[4]  C. S. Kow,et al.  Are severe asthma patients at higher risk of developing severe outcomes from COVID‐19? , 2020, Allergy.

[5]  J. Tate,et al.  Epidemiological Correlates of PCR Cycle Threshold Values in the Detection of SARS-CoV-2 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Shah,et al.  COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Xie,et al.  Asthma-associated risk for COVID-19 development , 2020, Journal of Allergy and Clinical Immunology.

[8]  K. Sakamaki,et al.  Mass Screening of Asymptomatic Persons for Severe Acute Respiratory Syndrome Coronavirus 2 Using Saliva , 2020, Clinical Infectious Diseases.

[9]  D. Halpin,et al.  Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? , 2020, The Lancet Respiratory Medicine.

[10]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[11]  Y. Otomo,et al.  Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series , 2020, PloS one.

[12]  He Yu,et al.  A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID‐19): A retrospective, multicenter, observational study , 2020, Immunity, inflammation and disease.

[13]  B. Lambrecht,et al.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.

[14]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[15]  S. Altın,et al.  Could ferritin level be an indicator of COVID‐19 disease mortality? , 2020, Journal of medical virology.

[16]  A. Olin,et al.  Small droplet emission in exhaled breath during different breathing manoeuvres: Implications for clinical lung function testing during COVID‐19 , 2020, Allergy.

[17]  S. Loosen,et al.  Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. , 2020, Journal of the American Society of Nephrology : JASN.

[18]  A. Pazin-Filho,et al.  Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) , 2020, Thrombosis Research.

[19]  R. Halwani,et al.  Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection , 2020, Annals of Nutrition and Metabolism.

[20]  P. Marik,et al.  Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study☆ , 2020, Medicine in Drug Discovery.

[21]  P. Morange,et al.  A granulocytic signature identifies COVID-19 and its severity , 2020, The Journal of infectious diseases.

[22]  Emma M Schatoff,et al.  D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19 , 2020, Thrombosis Research.

[23]  J. Thachil,et al.  Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients , 2020, Thrombosis Research.

[24]  W. Gianni,et al.  Serum Ferritin is an independent risk factor for Acute Respiratory Distress Syndrome in COVID-19 , 2020, Journal of Infection.

[25]  M. Loda,et al.  SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19 , 2020, Cancer Cell.

[26]  P. Legrand,et al.  May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? , 2020, Biochimie.

[27]  S. El-Chemaly,et al.  Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study , 2020, American journal of respiratory and critical care medicine.

[28]  U. Fresán,et al.  Independent Role of Severe Obesity as a Risk Factor for COVID‐19 Hospitalization: A Spanish Population‐Based Cohort Study , 2020, Obesity.

[29]  Benjamin S. Glicksberg,et al.  AKI in Hospitalized Patients with COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[30]  G. Lippi,et al.  Eosinophil count in coronavirus disease 2019: more doubts than answers , 2020, QJM : monthly journal of the Association of Physicians.

[31]  V. Fan,et al.  Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection , 2020, JAMA network open.

[32]  Eduardo Sánchez-Sánchez,et al.  Eating Habits and Physical Activity of the Spanish Population during the COVID-19 Pandemic Period , 2020, Nutrients.

[33]  P. Shi,et al.  In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age , 2020, PLoS biology.

[34]  Urvish K. Patel,et al.  Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis , 2020, BMJ Evidence-Based Medicine.

[35]  A. Robert,et al.  A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19) , 2020, Biomarker research.

[36]  Chaolin Huang,et al.  Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study , 2020, Virologica Sinica.

[37]  K. Granet,et al.  COVID-19 patients in a tertiary US hospital: Assessment of clinical course and predictors of the disease severity , 2020, Respiratory Medicine.

[38]  M. Marschollek,et al.  Risk factors for Covid-19 severity and fatality: a structured literature review , 2020, Infection.

[39]  J. Dillner,et al.  SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Ying Song,et al.  Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China , 2020, Hypertension Research.

[41]  Q. Ning,et al.  Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China , 2020, Critical Care.

[42]  Benjamin S. Glicksberg,et al.  Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[43]  J. Zein,et al.  SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry , 2020, EClinicalMedicine.

[44]  J. Mateo,et al.  Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19 , 2020, Frontiers in Medicine.

[45]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[46]  Ossama K. Abou Hassan,et al.  Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) , 2020, Clinical cardiology.

[47]  N. Awano,et al.  Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019 , 2020, Respiratory Investigation.

[48]  G. Pannone,et al.  An Overview of the Temporal Shedding of SARS-CoV-2 RNA in Clinical Specimens , 2020, Frontiers in Public Health.

[49]  D. Drömann,et al.  The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis , 2020, medRxiv.

[50]  E. K. Ha,et al.  Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study , 2020, Journal of Allergy and Clinical Immunology.

[51]  M. Abate,et al.  Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 , 2020, Kidney International.

[52]  K. Sakamaki,et al.  Mass screening of asymptomatic persons for SARS-CoV-2 using saliva , 2020, medRxiv.

[53]  K. Khunti,et al.  Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study , 2020, The Lancet Diabetes & Endocrinology.

[54]  Mingchun Ou,et al.  Risk factors of severe cases with COVID-19: a meta-analysis , 2020, Epidemiology and Infection.

[55]  S. Stranges,et al.  Mediterranean-Style Diet for the Primary and Secondary Prevention of Cardiovascular Disease: A Cochrane Review , 2020, Global heart.

[56]  M. Bassetti,et al.  Induction of ketosis as a potential therapeutic option to limit hyperglycemia and prevent cytokine storm in COVID-19 , 2020, Nutrition.

[57]  M. Jacquier,et al.  Alveolar SARS-CoV-2 viral load is tightly correlated with severity in COVID-19 ARDS , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Felipe García,et al.  Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study , 2020, AIDS.

[59]  H. Harapan,et al.  Remdesivir and its antiviral activity against COVID-19: A systematic review , 2020, Clinical Epidemiology and Global Health.

[60]  Ashley N Brown,et al.  Modeling the viral dynamics of SARS-CoV-2 infection , 2020, Mathematical Biosciences.

[61]  I. Martín-Antoniano,et al.  Cross‐sectional pilot study exploring the feasibility of a rapid SARS‐CoV‐2 immunization test in health and nonhealthcare workers , 2020, Allergy.

[62]  Zheng Liu,et al.  Delayed virus‐specific antibody responses associate with COVID‐19 mortality , 2020, Allergy.

[63]  Ankur Khajuria,et al.  The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis , 2020, Journal of medical virology.

[64]  D. Sin,et al.  COVID-19 and COPD , 2020, European Respiratory Journal.

[65]  C. Jesser,et al.  Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals , 2020, JAMA network open.

[66]  Y. Shoenfeld,et al.  Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation. , 2020, The Israel Medical Association journal : IMAJ.

[67]  R. Giacomelli,et al.  Ferritin and Severe COVID-19, from Clinical Observations to Pathogenic Implications and Therapeutic Perspectives. , 2020, The Israel Medical Association journal : IMAJ.

[68]  G. Soraya,et al.  Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis , 2020, Medicina Clínica (English Edition).

[69]  Fen Liu,et al.  Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients , 2020, Pharmacological Research.

[70]  A. Sheikh,et al.  Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19 , 2020, Allergy.

[71]  M. Karimi,et al.  Prevalence and clinical features of COVID-19 in Iranian patients with congenital coagulation disorders. , 2020, Blood transfusion = Trasfusione del sangue.

[72]  Changfeng Dong,et al.  Cardiac manifestations of COVID-19 in Shenzhen, China , 2020, Infection.

[73]  G. Passalacqua,et al.  COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey , 2020, Allergy.

[74]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[75]  Daishi Tian,et al.  D-dimer level is associated with the severity of COVID-19 , 2020, Thrombosis Research.

[76]  C. Castro,et al.  Determinants of COVID-19 disease severity in patients with underlying rheumatic disease , 2020, Clinical Rheumatology.

[77]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[78]  J. Weitz,et al.  COVID-19 coagulopathy, thrombosis, and bleeding , 2020, Blood.

[79]  A. Magis,et al.  Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19 , 2020, Critical Care.

[80]  Zumin Shi,et al.  Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis , 2020, Diabetes Research and Clinical Practice.

[81]  Simon A. Jones,et al.  Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. , 2020, JAMA.

[82]  M. Mahdavinia,et al.  Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019 , 2020, Annals of Allergy, Asthma & Immunology.

[83]  Y. Shoenfeld,et al.  COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy , 2020, Immunologic Research.

[84]  Abby L. Berns,et al.  Symptom Profiles of a Convenience Sample of Patients with COVID-19 — United States, January–April 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[85]  Faramarz Ismail-Beigi,et al.  Factors leading to high morbidity and mortality of COVID‐19 in patients with type 2 diabetes , 2020, Journal of diabetes.

[86]  Gilbert GREUB,et al.  Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses , 2020, Microbes and Infection.

[87]  P. Ye,et al.  Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19 , 2020, Hypertension.

[88]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[89]  M. Yekaninejad,et al.  A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[90]  M. Levine,et al.  COVID-19 severity is predicted by earlier evidence of accelerated aging , 2020, medRxiv.

[91]  Zhe Luo,et al.  D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study , 2020, Journal of Intensive Care.

[92]  R. Dobson,et al.  A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19 , 2020, EClinicalMedicine.

[93]  M. Rogero,et al.  Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19 , 2020, Free Radical Biology and Medicine.

[94]  D. Panigrahy,et al.  Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)? , 2020 .

[95]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[96]  Liyan Wen,et al.  Kinetics of viral load and antibody response in relation to COVID-19 severity. , 2020, The Journal of clinical investigation.

[97]  D. Panigrahy,et al.  Eicosanoids , 2020, The American Journal of Pathology.

[98]  M. Antonelli,et al.  Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort , 2020, EClinicalMedicine.

[99]  Heshui Shi,et al.  Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study , 2020, Diabetes Research and Clinical Practice.

[100]  M. Hayden Endothelial activation and dysfunction in metabolic syndrome, type 2 diabetes and coronavirus disease 2019 , 2020, The Journal of international medical research.

[101]  R. Hod,et al.  COVID-19 among Health Workers in Germany and Malaysia , 2020, International journal of environmental research and public health.

[102]  T. Bai,et al.  Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study , 2020, Hepatology.

[103]  M. Safford,et al.  Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  Patricia Harrington,et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection , 2020, Journal of Infection.

[105]  C. Micheletto,et al.  Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: Results from the Italian Severe Asthma Registry , 2020, Allergy.

[106]  S. Gilboa,et al.  Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[107]  Timothy Chevassut,et al.  COVID‐19 mortality in patients on anticoagulants and antiplatelet agents , 2020, British journal of haematology.

[108]  N. McElvaney,et al.  Characterization of the Inflammatory Response to Severe COVID-19 Illness , 2020, American journal of respiratory and critical care medicine.

[109]  K. Hoffmann‐Sommergruber,et al.  Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI) , 2020, Allergy.

[110]  G. Canonica,et al.  COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments , 2020, Allergy.

[111]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[112]  N. Zhong,et al.  Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China. , 2020, Bioscience trends.

[113]  Hongzhou Lu,et al.  The role of peripheral blood eosinophil counts in COVID‐19 patients , 2020, Allergy.

[114]  C. Torp‐Pedersen,et al.  Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.

[115]  Dechang Chen,et al.  Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis , 2020, Critical Care.

[116]  L. Price,et al.  Thrombosis and COVID-19 pneumonia: the clot thickens! , 2020, European Respiratory Journal.

[117]  Huan Li,et al.  D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis , 2020, BioMed research international.

[118]  Xin-chun Yang,et al.  Eosinopenia is associated with greater severity in patients with coronavirus disease 2019 , 2020, Allergy.

[119]  J. Bousquet,et al.  A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2 , 2020, Allergy.

[120]  W. Mcfarland,et al.  COVID-19 Among People Living with HIV: A Systematic Review , 2020, AIDS and Behavior.

[121]  Jianbo Tian,et al.  Clinical characteristics of COVID‐19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China , 2020, Journal of medical virology.

[122]  L. Montaner,et al.  Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts , 2020, Journal of leukocyte biology.

[123]  A. Carnahan,et al.  Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden , 2020, Acta Obstetricia et Gynecologica Scandinavica.

[124]  Fayzan F. Chaudhry,et al.  SARS-CoV-2 viral load predicts COVID-19 mortality , 2020, The Lancet Respiratory Medicine.

[125]  Chaofei Han,et al.  Procalcitonin levels in COVID-19 patients , 2020, International Journal of Antimicrobial Agents.

[126]  C. Akdis,et al.  Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients , 2020, Allergy.

[127]  L. Liang,et al.  Association of asthma and its genetic predisposition with the risk of severe COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[128]  J. Bousquet,et al.  Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement , 2020, Allergy.

[129]  Jie Bao,et al.  Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19 , 2020, Clinica Chimica Acta.

[130]  Kipp W. Johnson,et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.

[131]  O. Franco,et al.  Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis , 2020, European Journal of Epidemiology.

[132]  Kari C. Nadeau,et al.  Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors , 2020, Allergy.

[133]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[134]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[135]  Wei Liu,et al.  COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study , 2020, Hypertension Research.

[136]  L. Cecchi,et al.  Is asthma protective against COVID‐19? , 2020, Allergy.

[137]  L. Conte,et al.  Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection , 2020, Therapeutic advances in respiratory disease.

[138]  M. Ruíz-López,et al.  Changes in Dietary Behaviours during the COVID-19 Outbreak Confinement in the Spanish COVIDiet Study , 2020, Nutrients.

[139]  C. Gale,et al.  Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study , 2020, Brain, Behavior, and Immunity.

[140]  D. Abeni,et al.  Atopic status protects from severe complications of COVID‐19 , 2020, Allergy.

[141]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[142]  D. Bennett,et al.  Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19 , 2020, Journal of medical virology.

[143]  G. Chatellier,et al.  Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.

[144]  Chao Zhang,et al.  COVID-19 in people with HIV , 2020, The Lancet HIV.

[145]  R. López-Vélez,et al.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.

[146]  L. Barrea,et al.  Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey , 2020, Journal of Translational Medicine.

[147]  Alex Brito,et al.  Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis , 2020, Nutrients.

[148]  Ana C. Coelho,et al.  Is diet partly responsible for differences in COVID-19 death rates between and within countries? , 2020, Clinical and Translational Allergy.

[149]  M. Othman,et al.  Hemostatic laboratory derangements in COVID-19 with a focus on platelet count , 2020, Platelets.

[150]  S. Moiseev,et al.  Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID‐19 , 2020, Allergy.

[151]  E. Klang,et al.  Severe Obesity as an Independent Risk Factor for COVID‐19 Mortality in Hospitalized Patients Younger than 50 , 2020, Obesity.

[152]  R. José,et al.  Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome? , 2020, Obesity (Silver Spring, Md.).

[153]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[154]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[155]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[156]  M. Gleeson,et al.  Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London , 2020, Frontiers in Oncology.

[157]  Dean Billheimer,et al.  Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells , 2020, Journal of Allergy and Clinical Immunology.

[158]  Xuanzhe Zhang,et al.  Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study , 2020, Diabetes Care.

[159]  B. Southern Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. , 2020, Cleveland Clinic journal of medicine.

[160]  Feng Gao,et al.  Obesity Is a Risk Factor for Greater COVID-19 Severity , 2020, Diabetes Care.

[161]  G. Macedo,et al.  Review article: COVID‐19 and liver disease—what we know on 1st May 2020 , 2020, Alimentary pharmacology & therapeutics.

[162]  Kenar D. Jhaveri,et al.  Acute kidney injury in patients hospitalized with COVID-19 , 2020, Kidney International.

[163]  M. Revel,et al.  Pulmonary embolism in patients with COVID-19 pneumonia , 2020, European Respiratory Journal.

[164]  Cezmi A Akdis,et al.  Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19 , 2020, Allergy.

[165]  J. Wolchok,et al.  Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers , 2020, Cancer discovery.

[166]  S. Cao,et al.  Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 , 2020, European heart journal.

[167]  C. Akdis,et al.  Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status , 2020, Allergy.

[168]  W. Liang,et al.  Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China , 2020, Journal of Allergy and Clinical Immunology.

[169]  S. Solomon,et al.  Pre-existing traits associated with Covid-19 illness severity , 2020, PloS one.

[170]  D. Klonoff,et al.  Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States , 2020, Journal of diabetes science and technology.

[171]  Md. Saidur Rahman,et al.  Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response , 2020, Immunology Letters.

[172]  C. Graber,et al.  Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity , 2020, Emerging infectious diseases.

[173]  I. Amit,et al.  Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients , 2020, Cell.

[174]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[175]  S. Bonini,et al.  COVID‐19 Clinical trials: Quality matters more than quantity , 2020, Allergy.

[176]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[177]  Juping Du,et al.  Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count , 2020, Platelets.

[178]  P. Bánovčin,et al.  COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series , 2020, Allergy.

[179]  S. Sivapalaratnam,et al.  Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 , 2020, The New England journal of medicine.

[180]  J. Flynn,et al.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic , 2020 .

[181]  W. Liang,et al.  Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography , 2020, Cell.

[182]  Hongyang Wang,et al.  Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing , 2020, Cell Discovery.

[183]  Ahmad Khan,et al.  Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study , 2020, Gastroenterology.

[184]  S. Johnston Asthma and COVID‐19: Is asthma a risk factor for severe outcomes? , 2020, Allergy.

[185]  P. Ye,et al.  Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China , 2020, Hepatology.

[186]  L. Mombaerts,et al.  An interpretable mortality prediction model for COVID-19 patients , 2020, Nature Machine Intelligence.

[187]  Chuan Qin,et al.  Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China , 2020, JAMA network open.

[188]  R. Assaly,et al.  Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[189]  P. Scherer,et al.  The Role of Adipocytes and Adipocyte‐Like Cells in the Severity of COVID‐19 Infections , 2020, Obesity.

[190]  Z. Zhao,et al.  Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients , 2020, Theranostics.

[191]  F. Shan,et al.  CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients , 2020, Theranostics.

[192]  D. Halpin,et al.  Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective , 2020, European Respiratory Journal.

[193]  M. Rothenberg,et al.  Eosinophil responses during COVID-19 infections and coronavirus vaccination , 2020, Journal of Allergy and Clinical Immunology.

[194]  N. Liu,et al.  Clinical course and risk factors for recurrence of positive SARS-CoV-2 RNA: a retrospective cohort study from Wuhan, China , 2020, medRxiv.

[195]  M. Smithgall,et al.  Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2 , 2020, bioRxiv.

[196]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[197]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[198]  P. Gergen,et al.  Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 , 2020, Journal of Allergy and Clinical Immunology.

[199]  Iain B McInnes,et al.  Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. , 2020, Circulation.

[200]  G. Lippi,et al.  Eosinophil count in severe coronavirus disease 2019 (COVID-19) , 2020, QJM : monthly journal of the Association of Physicians.

[201]  Hong Zhang,et al.  The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan , 2020, Diabetes, obesity & metabolism.

[202]  M. Zheng,et al.  Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease , 2020, Metabolism.

[203]  J. Soriano,et al.  Advanced forecasting of SARS‐CoV‐2‐related deaths in Italy, Germany, Spain, and New York State , 2020, Allergy.

[204]  Youdong Wei,et al.  Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis , 2020, British journal of haematology.

[205]  Dong Men,et al.  Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases.

[206]  Nathaniel Hupert,et al.  Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.

[207]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[208]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[209]  Qi Zhou,et al.  Mechanism of thrombocytopenia in COVID-19 patients , 2020, Annals of Hematology.

[210]  Yuyang Cai,et al.  Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19 , 2020, Respiratory Research.

[211]  F. Cheng,et al.  Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China , 2020, Clinical Microbiology and Infection.

[212]  R. José,et al.  Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome? , 2020, Obesity.

[213]  Haibo Xu,et al.  Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China , 2020, Critical Care.

[214]  C. Akdis,et al.  Distinct characteristics of COVID‐19 patients with initial rRT‐PCR‐positive and rRT‐PCR‐negative results for SARS‐CoV‐2 , 2020, Allergy.

[215]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[216]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[217]  Mario Plebani,et al.  Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.

[218]  Yan Zhao,et al.  Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 , 2020, Journal of Infection.

[219]  Ruoqing Li,et al.  Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China , 2020, Journal of Clinical Virology.

[220]  M. Zuin,et al.  Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome , 2020, Journal of Clinical Virology.

[221]  Anna Stachel,et al.  Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[222]  J. Rello,et al.  SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria , 2020, Anaesthesia Critical Care & Pain Medicine.

[223]  T. Henry,et al.  Chest Computed Tomography for Detection of Coronavirus Disease 2019 (COVID-19): Don't Rush the Science , 2020, Annals of Internal Medicine.

[224]  A. Carr A new clinical trial to test high-dose vitamin C in patients with COVID-19 , 2020, Critical Care.

[225]  A. Mantovani,et al.  Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[226]  Zhiyong Ma,et al.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.

[227]  W. Grant,et al.  Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths , 2020, Nutrients.

[228]  M. Choolani,et al.  Coronavirus disease 2019 (COVID-19) pandemic and pregnancy , 2020, American Journal of Obstetrics and Gynecology.

[229]  D. Sin,et al.  ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 , 2020, European Respiratory Journal.

[230]  Lei Dong,et al.  Kidney disease is associated with in-hospital death of patients with COVID-19 , 2020, Kidney International.

[231]  J. Patel,et al.  COVID-19 and the liver: little cause for concern , 2020, The Lancet Gastroenterology & Hepatology.

[232]  B. Song,et al.  Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review , 2020, European Radiology.

[233]  Sharukh Lokhandwala,et al.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.

[234]  Malik Peiris,et al.  Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.

[235]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[236]  Qiu Zhao,et al.  Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[237]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[238]  G. Remuzzi,et al.  COVID-19 and Italy: what next? , 2020, The Lancet.

[239]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[240]  M. Lipsitch,et al.  Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.

[241]  Lei Liu,et al.  Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China , 2020, Diabetes Care.

[242]  C Chen,et al.  [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. , 2020, Zhonghua xin xue guan bing za zhi.

[243]  Mario Plebani,et al.  Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis , 2020, Clinica Chimica Acta.

[244]  Chao Zhang,et al.  Liver injury in COVID-19: management and challenges , 2020, The Lancet Gastroenterology & Hepatology.

[245]  Wenzhen Zhu,et al.  Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes , 2020, Investigative radiology.

[246]  Dong Men,et al.  Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients , 2020, medRxiv.

[247]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[248]  K. Hoffmann‐Sommergruber,et al.  EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma , 2020, Allergy.

[249]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[250]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[251]  王华英,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[252]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[253]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[254]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[255]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[256]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[257]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[258]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[259]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[260]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[261]  Bachti Alisjahbana,et al.  C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis , 2020, Therapeutic advances in respiratory disease.

[262]  G. Martin,et al.  Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. , 2019, JAMA.

[263]  K. Faber,et al.  Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases , 2019, Front. Immunol..

[264]  P. Calder,et al.  Immune Function and Micronutrient Requirements Change over the Life Course , 2018, Nutrients.

[265]  Liang Wang,et al.  Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study , 2018, Scientific Reports.

[266]  J. Slavin,et al.  Health Effects and Sources of Prebiotic Dietary Fiber , 2018, Current developments in nutrition.

[267]  A. Carr,et al.  Vitamin C and Immune Function , 2017, Nutrients.

[268]  S. Johnston,et al.  The influence of asthma control on the severity of virus-induced asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[269]  Jie Du,et al.  Vitamin D Receptor Inhibits Nuclear Factor κB Activation by Interacting with IκB Kinase β Protein* , 2013, The Journal of Biological Chemistry.

[270]  K. Ward,et al.  Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[271]  R. Callister,et al.  The expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis? , 2011, Placenta.

[272]  I. D. de Boer,et al.  Relations of Dietary Magnesium Intake to Biomarkers of Inflammation and Endothelial Dysfunction in an Ethnically Diverse Cohort of Postmenopausal Women , 2009, Diabetes Care.

[273]  M. Karin,et al.  The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .

[274]  W. Yancy,et al.  A review of low-carbohydrate ketogenic diets , 2003, Current atherosclerosis reports.

[275]  M. Parmentier,et al.  Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation* , 2003, Journal of Biological Chemistry.

[276]  W. Hörl,et al.  Anti‐inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL‐12 and up‐regulation of IL‐10 production , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[277]  K. Tanaka,et al.  Effects of protein calorie malnutrition on tuberculosis in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[278]  Daishi Tian,et al.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .

[279]  K. Dyer,et al.  Eosinophils and their interactions with respiratory virus pathogens , 2009, Immunologic research.

[280]  M. Karin,et al.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity. , 2004, Trends in immunology.

[281]  … and in asthma , 1995 .

[282]  AND COVID-19 , 2022 .